Midostaurin with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia
Midostaurin with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia
Country | Agency | Status | Link | Details of us |
---|---|---|---|---|
Austria | LBI-HTA | 2017 | LINK | No changes, inclusion in LBI-HTA Horizon Scanning in Oncology Series and dissemination to drug commissions. |
Austria | GOEG | Ongoing | – | Dissemination to the decision-maker. |
Belgium | RVIZ | 2018 | – | National adaptation. |
Croatia | AAZ | 2017 | – | A summary of the report was prepared in the national language, as well as assessment elements B0001 and A0020, with links to the full report on English language. Upon Croatian decision makers request on this topic, the report will be updated if needed and local information will be added (i.e., epidemiological information such as patient numbers; the technologies available in Croatia, information about costs…), including recommendations. |
Czech Republic | SUKL | Ongoing | – | National adaptation. Added local information. Translation of key summaries into national language. |
Denmark | Danish Medicines Council | 2018 | LINK | Used for background information. |
France | HAS | Ongoing | – | Cited in the national report as background or additional information. |
Hungary | UNIBA | 2018-19 | – | National Adaptation. Added local information. |
Italy | AIFA | 2017 | – | Used for background information |
Poland | UNIBA | 2019 | – | National Adaptation. Added local information. |
Portugal | INFARMED | 2018 | – | National adaptation: Use of the EUnetHTA assessment to support the production of the national report, including citation in the national report, use of the EUnetHTA literature searches, minor changes to the content in the EUnetHTA assessment and addition of local information. |
Slovakia | UNIBA | 2018 | – | National Adaptation. Added local information. Used the assessment to inform the evaluation or consideration of a company submission of evidence. |
Spain | AEMPS | 2017 | – | Cited in the national report as background or additional information. |
Spain | AETSA | 2018 | LINK | A summary of this EUnetHTA assessment in Spanish together with the full English report has been published on AETSA’s website for dissemination. In addition, the report has been distributed to the regional decision-maker and haematologists |
Sweden | TLV | 2018 | – | National adaptation. Cited in the national report as background or additional information. Added local information and cost effectiveness analysis. |
UK (England) | NICE | 2017 | LINK | EUnetHTA reports are indexed in NHS Evidence, a public database which provides access to selected sources of evidence in health, social case and public health. |
UK (Scotland) | SMC | 2018 | LINK | Used for validation of submission from the technology developer. |